Skip to main content
PCRX
NASDAQ Life Sciences

Doma Perpetual Exits 5% Stake in Pacira, Selling 2.9M Shares at $36.29 on Deal Announcement Day

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$36.38
Mkt Cap
$1.447B
52W Low
$18.8
52W High
$36.46
52W Position info
94% above low
Off High info
at 52W high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

PCRX sits 94% above its 52-week low of $18.8 on elevated volume (1.9× avg).

Summary

Doma Perpetual Capital Management and affiliates sold their entire 5%+ stake in Pacira BioSciences on the day the Viatris acquisition was announced, disposing of 2.9 million shares at $36.29 per share.


Key Events · Ownership and Investor Activity · PCRX

  • Doma Perpetual Exits 5% Stake

    Doma Perpetual Capital Management and affiliates sold 2,936,784 shares at $36.29 per share on October 8, 2026, reducing their aggregate beneficial ownership to 0% and ceasing to be 5% owners.

  • Sale Coincides with Viatris Deal Announcement

    The sales occurred on the same day Viatris announced its $36.50 per share all-cash acquisition of Pacira, with the sale price of $36.29 just below the deal price.

  • Transaction Breakdown

    Doma Master Fund sold 1,965,765 shares, The John Templeton Foundation sold 812,019 shares, and Pedro Escudero sold 159,000 shares, plus 10 shares sold on October 13, 2026.

  • No Remaining Position

    All reporting persons now report zero shares beneficially owned, representing a complete exit from the position.


Analysis · PCRX · Life Sciences

On October 8, 2026, the same day Viatris announced its $36.50 per share all-cash acquisition, Doma Perpetual Capital Management and affiliated entities sold their entire 5%+ position in Pacira BioSciences. The group disposed of 2,936,784 shares at $36.29 per share, just below the deal price, and now reports zero beneficial ownership. This complete exit by a significant institutional holder, executed at the acquisition announcement, removes a potential overhang and confirms the holder's decision to monetize rather than hold through closing.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PCRX was trading at $36.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $18.80 to $36.46. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PCRX - Latest Insights

PCRX
Nov 05, 2026, 4:37 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $36.42
Real-time Price: $36.60 info
Change: +$0.180 (+0.49%) info
Market Cap: $1.463B info
PCRX
Nov 05, 2026, 4:33 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.42
Real-time Price: $36.60 info
Change: +$0.180 (+0.49%) info
Market Cap: $1.463B info
PCRX
Oct 30, 2026, 8:32 AM EDT
Filing Type: SC 14D9
Importance Score:
8
Price at Filing: $36.35
Real-time Price: $36.60 info
Change: +$0.250 (+0.69%) info
Market Cap: $1.463B info
PCRX
Oct 08, 2026, 9:24 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $36.34
Real-time Price: $36.60 info
Change: +$0.260 (+0.72%) info
Market Cap: $1.463B info
PCRX
Oct 08, 2026, 7:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $25.72
Real-time Price: $36.60 info
Change: +$10.88 (+42%) info
Market Cap: $1.463B info